RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
| RAPT Stock | USD 1.23 0.11 9.82% |
Slightly above 55% of RAPT Therapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading RAPT Therapeutics stock suggests that some investors are interested at this time. RAPT Therapeutics' investing sentiment can be driven by a variety of factors including economic data, RAPT Therapeutics' earnings reports, geopolitical events, and overall market trends.
RAPT |
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 -- RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on We
Read at finance.yahoo.com
 |
RAPT Therapeutics Fundamental Analysis
We analyze RAPT Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
RAPT Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
RAPT Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with RAPT Therapeutics stock to make a market-neutral strategy. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics with similar companies.
Peers
RAPT Therapeutics Related Equities
| PEPG | PepGen | 6.69 | ||||
| CNTB | Connect Biopharma | 6.19 | ||||
| ARVN | Arvinas | 6.13 | ||||
| GLUE | Monte Rosa | 5.93 | ||||
| MLYS | Mineralys Therapeutics, | 4.71 | ||||
| BDTX | Black Diamond | 4.05 | ||||
| MOLN | Molecular Partners | 3.19 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
| XLO | Xilio Development | 2.02 | ||||
| TYRA | Tyra Biosciences | 1.78 | ||||
| PLRX | Pliant Therapeutics | 1.42 | ||||
| STOK | Stoke Therapeutics | 1.19 | ||||
| RLAY | Relay Therapeutics | 0.84 | ||||
| PMVP | Pmv Pharmaceuticals | 0.63 | ||||
| HOWL | Werewolf Therapeutics | 0.51 | ||||
| IKNA | Ikena Oncology | 1.17 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| ANTX | AN2 Therapeutics | 1.44 | ||||
| DSGN | Design Therapeutics | 2.93 | ||||
| PHVS | Pharvaris | 7.49 | ||||
| HCWB | HCW Biologics | 10.71 |
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.